Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibrutinib - Janssen/Pharmacyclics

Next Previous
Drug Profile

Ibrutinib - Janssen/Pharmacyclics

Alternative Names: CRA-032765; IMBRUVICA; Imbruvica; ImBurvica; JNJ-54179060; PCI-32765

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celera Genomics Group
  • Developer Bristol-Myers Squibb; Celgene Corporation; Foundation GIMEMA; Genentech; Janssen; Janssen Biotech; Lymphoma Academic Research Organisation; National Cancer Institute (USA); Northwestern University; OHSU Knight Cancer Institute; Pharmacyclics; Sheba Medical Center; Singapore General Hospital; Stanford University Medical Center; Thomas Jefferson University; University Hospital Muenster; University of California, Davis; University of California, San Diego
  • Class 2 ring heterocyclic compounds; Antiallergics; Antineoplastics; Antirheumatics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Graft-versus-host disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Pancreatic cancer
  • Phase II Acute myeloid leukaemia; B-cell lymphoma; CNS cancer; Hairy cell leukaemia; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; SARS-CoV-2 acute respiratory disease; Solid tumours; Squamous cell cancer; T-cell prolymphocytic leukaemia
  • Phase I/II Gastrointestinal cancer; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • No development reported Cancer; Colorectal cancer; Lymphoma; Myelodysplastic syndromes
  • Discontinued Breast cancer; Rheumatoid arthritis; Seasonal allergic rhinitis

Most Recent Events

  • 27 Mar 2024 Pharmacyclics and Janssen Research and Development completes the phase II CAPTIVATE trial in Chronic lymphocytic leukaemia (Combination therapy, First line therapy) in USA, Australia, Italy, New Zealand, Spain and Poland (NCT02910583)
  • 01 Feb 2024 Janssen Research & Development initiates enrolment in the phase-II TAILOR trial for Chronic lymphocytic leukaemia (Combination therapy, Monotherapy, First-line therapy) in USA (NCT05963074),
  • 02 Jan 2024 The University of Birmingham completes the phase II IciCLLe trial for Chronic lymphocytic leukaemia in United Kingdom (ISRCTN12695354) ( EudraCT2012-003608-11)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top